DMRA
Damora Therapeutics, Inc.
Damora Therapeutics, Inc. insider trading
Insiders at Damora Therapeutics, Inc. have been buying its stock on the open market. The largest purchase in the last 30 days was Jarrett Jennifer (Director, President and CEO) buying $252.9K of DMRA, filed Sep 28, 2026. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
- Bought on the open market
- $252.9K
- Sold
- —
- Insiders
- 1
- Latest trade
- Sep 25, 2026
From SEC filings · last 30 days
Recent DMRA insider transactions
Jarrett JenniferDirector, President and CEO
Bought 12,500 sh at $20.23 · Sep 25, 2026
$252.9K
Filing
SEC Form 4 data, Q3 2024 to Q2 2026
DMRA insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 3 insiders traded DMRA on the open market: 0 purchases and 9 sales worth $38.8K. In the last four quarters alone: 0 purchases and 6 sales ($27.2K), by 3 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | −$23.3K3 sales | |
| Q4 2025 | — | — | |
| Q3 2025 | — | −$3.9K3 sales | |
| Q2 2025 | — | — | |
| Q1 2025 | — | −$11.6K3 sales | |
| Q4 2024 | — | — | |
| Q3 2024 | — | — |
- Largest sale
- −$15K of DMRA by Schambye Hans T. (Chief Executive Officer · Director) on Jan 02, 2026.
Open-market transactions through Jun 30, 2026most recent first
Schambye Hans T.
Chief Executive Officer · Director
−$15K
Jan 02, 2026
700 sh · $21.38
Winslow Garrett
General Counsel
−$5.5K
Jan 02, 2026
255 sh · $21.38
Firmani Lori
Chief Financial Officer
−$2.9K
Jan 02, 2026
135 sh · $21.41
Schambye Hans T.
Chief Executive Officer · Director
−$2.5K
Jul 03, 2025
735 sh · $3.38
Winslow Garrett
General Counsel
−$881
Jul 03, 2025
260 sh · $3.39
Firmani Lori
Interim CFO
−$498
Jul 03, 2025
147 sh · $3.39
Schambye Hans T.
Chief Executive Officer · Director
−$7.5K
Jan 03, 2025
1,341 sh · $5.60
Winslow Garrett
General Counsel
−$2.6K
Jan 03, 2025
471 sh · $5.60
Firmani Lori
Interim CFO
−$1.5K
Jan 03, 2025
261 sh · $5.63
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jan 02, 2026 | Schambye Hans T.Chief Executive Officer · Director | 700 | $21.38 | −$15K |
| Jan 02, 2026 | Winslow GarrettGeneral Counsel | 255 | $21.38 | −$5.5K |
| Jan 02, 2026 | Firmani LoriChief Financial Officer | 135 | $21.41 | −$2.9K |
| Jul 03, 2025 | Schambye Hans T.Chief Executive Officer · Director | 735 | $3.38 | −$2.5K |
| Jul 03, 2025 | Winslow GarrettGeneral Counsel | 260 | $3.39 | −$881 |
| Jul 03, 2025 | Firmani LoriInterim CFO | 147 | $3.39 | −$498 |
| Jan 03, 2025 | Schambye Hans T.Chief Executive Officer · Director | 1,341 | $5.60 | −$7.5K |
| Jan 03, 2025 | Winslow GarrettGeneral Counsel | 471 | $5.60 | −$2.6K |
| Jan 03, 2025 | Firmani LoriInterim CFO | 261 | $5.63 | −$1.5K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check DMRA — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Damora Therapeutics, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- Are DMRA insiders buying or selling?
- Between Sep 25, 2026 and Sep 25, 2026, 1 Damora Therapeutics, Inc. insider made 1 open-market purchase worth $252.9K and no sales, a net purchase of $252.9K.
- How much DMRA stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 3 Damora Therapeutics, Inc. insiders made no open-market purchases and 9 sales worth $38.8K. In the four quarters to Jun 30, 2026: no purchases and 6 sales ($27.2K). The largest sale was Schambye Hans T. selling $15K on Jan 02, 2026.
- What was the largest recent DMRA insider trade?
- Jarrett Jennifer (Director, President and CEO) bought $252.9K of DMRA stock on Sep 25, 2026 at about $20.23 a share.
- When did an insider last buy DMRA shares?
- The most recent open-market purchase on file is Jarrett Jennifer (Director, President and CEO) buying $252.9K on Sep 25, 2026.
- Where does DMRA insider trading data come from?
- From the Form 4 filings Damora Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.